References
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P et al (2003) Adverse reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48:201–206
Brouard M, Saurat JH (2001) Cutaneous reactions to STI571. N Engl J Med 345:618–619
Keechilat P, Mathew T (2005) Imatinib induced Stevens–Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 71(4):288–289
Vidal D, Puig L, Sureda A, Alomar A (2002) STI571-induced Stevens–Johnson syndrome. Br J Haematol 119:274–275
Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS et al (2002) Stevens–Johnson syndrome after treatment with STI571: a case report. Br J Haematol 117:620–622
Rule SA, O’Brien SG, Crossman LC (2002) Managing cutaneous reactions to imatinib therapy. Blood 100:3434–3435
Shah N, Pasquini R, Rousselet P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ (2006) Dasatanib vs escalated dose of imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of the CA180-017 START-R randomized study. Blood 108:167a
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahapatra, M., Mishra, P. & Kumar, R. Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 86, 537–538 (2007). https://doi.org/10.1007/s00277-007-0265-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-007-0265-y